TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31244884

Group type: EXPERIMENTAL
Intervention: Anthocyanin supplementation
Number of subjects: 27
Study: 31245054

Group type: EXPERIMENTAL
Intervention: Subcutaneous abatacept 125 mg weekly for 24 weeks
Number of subjects: 425

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 425
Study: 31245160

Group type: EXPERIMENTAL
Intervention: Intraoperative endoscopic submucosal injection of dual tracer (radioisotope and indocyanine green) with sentinel basins detected using gamma-probe
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Endoscopic injection of indocyanine green (ICG) with sentinel basins detected using a fluorescence imaging system
Number of subjects: 237

Group type: COMPARATOR
Intervention: Standard laparoscopic gastrectomy with lymphadenectomy
Number of subjects: 237
Study: 31245263

Group type: EXPERIMENTAL
Intervention: STRIDE intervention involving a nurse falls care manager who assesses risks, suggests interventions, and creates individualized care plans.
Number of subjects: 5451

Group type: EXPERIMENTAL
Intervention: Administrative data used for adjudication of serious fall injuries.
Number of subjects: 5451

Group type: EXPERIMENTAL
Intervention: Participant self-report of falls leading to medical attention identified during telephone interviews every 4 months.
Number of subjects: 5451
Study: 31246115

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31246132

Group type: EXPERIMENTAL
Intervention: non-invasive vagus nerve stimulation (nVNS)
Number of subjects: 225

Group type: COMPARATOR
Intervention: sham
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: nVNS
Number of subjects: 225
Study: 31246360

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 229
Study: 31246589

Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitors (evolocumab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inclisiran (siRNA)
Number of subjects: 0
Study: 31247117

Group type: EXPERIMENTAL
Intervention: 10 mg adefovir-dipivoxil (OAT1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pitavastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 0
Study: 31249371

Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure monitoring for 24 hours
Number of subjects: 22
Study: 31249402

Group type: EXPERIMENTAL
Intervention: Creatinine-based estimated glomerular filtration rate (eGFR) analysis in subjects with native kidneys
Number of subjects: 31
Study: 31249784

Group type: EXPERIMENTAL
Intervention: Sebelipase alfa
Number of subjects: 1
Study: 31249919

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 31249987

Group type: EXPERIMENTAL
Intervention: Patient management strategies for isolated distal deep-vein thrombosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient management strategies for proximal deep-vein thrombosis
Number of subjects: 0
Study: 31249989

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31250322

Group type: EXPERIMENTAL
Intervention: Brivaracetam oral solution (dosage increased weekly: 0.8, 1.6, 3.2 mg/kg/day for patients ≥ 8 years; 1.0, 2.0, 4.0 mg/kg/day for patients < 8 years)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Brivaracetam oral solution
Number of subjects: 100
Study: 31250408

Group type: EXPERIMENTAL
Intervention: POCS-guided electrohydraulic or laser lithotripsy
Number of subjects: 156
Study: 31250427

Group type: EXPERIMENTAL
Intervention: MedSafer electronic decision support tool for deprescribing
Number of subjects: 1066

Group type: COMPARATOR
Intervention: Usual care (medication reconciliation)
Number of subjects: 1066
Study: 31250445

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment (selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, or vortioxetine) for 8 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (41 healthy controls)
Number of subjects: 58
Study: 31250829

Group type: EXPERIMENTAL
Intervention: Feminizing hormone therapy and adherence counseling; Peer health navigation
Number of subjects: 0
Study: 31251090

Group type: EXPERIMENTAL
Intervention: mepolizumab single-use prefilled autoinjector
Number of subjects: 0
Study: 31251440

Group type: EXPERIMENTAL
Intervention: Changes in sputum neutrophils
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Changes in sputum eosinophils
Number of subjects: 40
Study: 31251543

Group type: EXPERIMENTAL
Intervention: 0.3% A/BPO treatment
Number of subjects: 50
Study: 31252347

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention to delay repeat pregnancy
Number of subjects: 331

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 331
Study: 31253124

Group type: EXPERIMENTAL
Intervention: Cetuximab-based infusional 5-fluorouracil regimen
Number of subjects: 120
Study: 31253196

Group type: EXPERIMENTAL
Intervention: Major Depressive Disorder (MDD)
Number of subjects: 1112

Group type: EXPERIMENTAL
Intervention: Posttraumatic Stress Disorder (PTSD)
Number of subjects: 1112

Group type: COMPARATOR
Intervention: Schizophrenia Spectrum Disorders (SSD)
Number of subjects: 1112

Group type: COMPARATOR
Intervention: General Population
Number of subjects: 1112
Study: 31253237

Group type: EXPERIMENTAL
Intervention: Proactive outreach
Number of subjects: 2654

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 2654
Study: 31253437

Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Single Disorder Protocol (SDP)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 223
Study: 31253540

Group type: EXPERIMENTAL
Intervention: Tezacaftor/ivacaftor
Number of subjects: 70
Study: 31253572

Group type: EXPERIMENTAL
Intervention: IPH4102 (monoclonal antibody targeting KIR3DL2) administered as an intravenous infusion at a flat dose of 750 mg during cohort-expansion.
Number of subjects: 44
Study: 31253596

Group type: EXPERIMENTAL
Intervention: AMG 232 monotherapy (arm 1) at doses of 60, 120, 240, 360, 480, or 960 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: AMG 232 at 60 mg with trametinib 2 mg (arm 2)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Common treatment-related AEs for AMG 232
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Pharmacokinetics of AMG 232
Number of subjects: 36
Study: 31253622

Group type: EXPERIMENTAL
Intervention: All-site screening for CT/NG infections
Number of subjects: 1610

Group type: COMPARATOR
Intervention: Pharyngeal screening
Number of subjects: 1610

Group type: COMPARATOR
Intervention: Rectal screening
Number of subjects: 1610

Group type: COMPARATOR
Intervention: Urethral screening
Number of subjects: 1610
Study: 31253623

Group type: EXPERIMENTAL
Intervention: Infants in the HELMi cohort receiving various environmental, lifestyle, and genetic factors assessments through faecal samples and questionnaires.
Number of subjects: 1055

Group type: EXPERIMENTAL
Intervention: Motor and cognitive developmental screening at 18 months.
Number of subjects: 1055
Study: 31253624

Group type: EXPERIMENTAL
Intervention: Multiresistant bacteria (MRB) carriage
Number of subjects: 5117

Group type: EXPERIMENTAL
Intervention: CPE
Number of subjects: 5117

Group type: EXPERIMENTAL
Intervention: MRSA
Number of subjects: 5117

Group type: EXPERIMENTAL
Intervention: VRE
Number of subjects: 5117

Group type: EXPERIMENTAL
Intervention: ESBL
Number of subjects: 5117
Study: 31253727

Group type: EXPERIMENTAL
Intervention: ART+Peg-IFN-α2a after 5 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peg-IFN-α2a monotherapy after 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peg-IFN-α2a immunotherapy
Number of subjects: 0
Study: 31253732

Group type: EXPERIMENTAL
Intervention: Self-reported questionnaires including the Hospital Anxiety and Depression Scale, the Functional Assessment of Cancer Therapy (FACT), General and Brain (FACT-Br), and the Leisure Time Physical Activity Questionnaire.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telephone interviews with patients and caregivers.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Advance care planning discussions.
Number of subjects: 0
Study: 31254057

Group type: EXPERIMENTAL
Intervention: WTC workers with lower airway disease
Number of subjects: 207

Group type: COMPARATOR
Intervention: COPDGene® WTC-unexposed and asymptomatic subjects
Number of subjects: 207
Study: 31254174

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 103101

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 103101
Study: 31254223

Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31254273

Group type: EXPERIMENTAL
Intervention: Plazomicin-based combination therapy (with adjunctive tigecycline or meropenem)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tigecycline
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (Colistin-based combination therapy)
Number of subjects: 15
Study: 31254392

Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir (G/P) 300 mg/120 mg once daily for 8-16 weeks
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir (G/P)
Number of subjects: 48
Study: 31255290

Group type: EXPERIMENTAL
Intervention: Closed-loop vasopressor (CLV) control with norepinephrine infusion
Number of subjects: 20
Study: 31255472

Group type: EXPERIMENTAL
Intervention: Cook Zenith p-Branch stent graft
Number of subjects: 30
Study: 31255562

Group type: EXPERIMENTAL
Intervention: PASCAL Transcatheter Valve Repair System
Number of subjects: 62
Study: 31255638

Group type: EXPERIMENTAL
Intervention: Foot Function Index (FFI)
Number of subjects: 26
Study: 31255846

Group type: EXPERIMENTAL
Intervention: Electrical storm (ES) in LVAD patients
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Patients experiencing ES
Number of subjects: 652
Study: 31255895

Group type: EXPERIMENTAL
Intervention: Coronary Angiography (CAG)
Number of subjects: 10266

Group type: EXPERIMENTAL
Intervention: Index Revascularization
Number of subjects: 10266

Group type: EXPERIMENTAL
Intervention: Urgent Revascularization for very-high-risk patients
Number of subjects: 10266

Group type: EXPERIMENTAL
Intervention: Early Revascularization for high-risk patients
Number of subjects: 10266

Group type: EXPERIMENTAL
Intervention: In-hospital Major Adverse Cardio-Cerebral Events (MACCE)
Number of subjects: 10266

Group type: EXPERIMENTAL
Intervention: Length of Stay (LOS)
Number of subjects: 10266
Study: 31255969

Group type: EXPERIMENTAL
Intervention: 8-week weight loss period (≥8% of body weight)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Weight maintenance period with medium to high dietary protein
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Baseline measurement
Number of subjects: 24
Study: 31256001

Group type: EXPERIMENTAL
Intervention: Current treatments for anxiety (psychological and pharmacological)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neural circuitry modulation by current treatments
Number of subjects: 0
Study: 31256022

Group type: EXPERIMENTAL
Intervention: Viral pattern (chronic HBV or HCV)
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Metabolic pattern (≥2 metabolic, no lifestyle or viral)
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Lifestyle pattern (current smoker or alcohol user, no viral)
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Viral+metabolic risk factors
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Lifestyle+viral risk factors
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Lifestyle+metabolic risk factors but not viral
Number of subjects: 1004
Study: 31256026

Group type: EXPERIMENTAL
Intervention: Secure prescription pads for zolpidem
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epidemiological study of the French National Health Insurance database
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Field studies of prescribers and consumers of zolpidem
Number of subjects: 0
Study: 31256030

Group type: EXPERIMENTAL
Intervention: Multimodal imaging and image review by an ophthalmic grader
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current standard of care (evaluation of patients in clinic by an ophthalmologist)
Number of subjects: 0
Study: 31256258

Group type: EXPERIMENTAL
Intervention: First-trimester Perceived Stress Scale (PSS) scores
Number of subjects: 4161

Group type: EXPERIMENTAL
Intervention: Third-trimester Perceived Stress Scale (PSS) scores
Number of subjects: 4161

Group type: EXPERIMENTAL
Intervention: PSS scores 2-7 years after delivery
Number of subjects: 4161

Group type: EXPERIMENTAL
Intervention: First-trimester PSS and PSS increase through pregnancy
Number of subjects: 4161

Group type: EXPERIMENTAL
Intervention: Presence of APOs (HDP, PE, miPTB)
Number of subjects: 4161
Study: 31256293

Group type: EXPERIMENTAL
Intervention: Overcontrol in Youth Checklist (OCYC)
Number of subjects: 0
Study: 31256774

Group type: EXPERIMENTAL
Intervention: Post-operative multimodal analgesic regimen
Number of subjects: 1212
Study: 31256778

Group type: EXPERIMENTAL
Intervention: Fast-track protocols in THA/TKA
Number of subjects: 36608
Study: 31256779

Group type: EXPERIMENTAL
Intervention: taTME
Number of subjects: 40

Group type: COMPARATOR
Intervention: CLS
Number of subjects: 40

Group type: COMPARATOR
Intervention: SPLS
Number of subjects: 40
Study: 31257724

Group type: EXPERIMENTAL
Intervention: Obinutuzumab (1000 mg) plus IVIG
Number of subjects: 25
Study: 31258695

Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 45
Study: 31258922

Group type: EXPERIMENTAL
Intervention: Biomarker identification for disease progression
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Blood samples, lung function tests, quality of life questionnaires, bronchoscopy (subgroup)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Blinded home handheld spirometry
Number of subjects: 200

Group type: COMPARATOR
Intervention: Idiopathic pulmonary fibrosis (as positive control)
Number of subjects: 200
Study: 31259266

Group type: EXPERIMENTAL
Intervention: NOAC
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Vitamin K antagonists
Number of subjects: 4000

Group type: COMPARATOR
Intervention: No anticoagulant
Number of subjects: 4000
Study: 31259847

Group type: EXPERIMENTAL
Intervention: University of Pennsylvania Smell Identification Test
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Smell Threshold Test
Number of subjects: 51
Study: 31260802

Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 42
Study: 31260835

Group type: EXPERIMENTAL
Intervention: GSK2879552 (0.25 mg-3 mg once daily and 3-mg or 4-mg intermittent dosing)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: GSK2879552
Number of subjects: 29
Study: 31261514

Group type: EXPERIMENTAL
Intervention: Apatinib plus docetaxel (docetaxel 75 mg/m² i.v. on day 1 plus oral apatinib 250 mg/day)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Apatinib plus docetaxel
Number of subjects: 14
Study: 31262301

Group type: EXPERIMENTAL
Intervention: 1-year intensive lifestyle intervention (ILI) program
Number of subjects: 180
Study: 31262320

Group type: EXPERIMENTAL
Intervention: Target-to-target pointing task in a virtual environment using a haptic stylus
Number of subjects: 64
Study: 31262327

Group type: EXPERIMENTAL
Intervention: Proteomic analysis of plasma from patients with AIS due to LVO
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Four-protein panel (PPBP, THBS1, LYVE1, IGF2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IGF2, LYVE1, THBS1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Western blots analysis
Number of subjects: 40
Study: 31262337

Group type: EXPERIMENTAL
Intervention: Carotid plaque burden and size of plaque compositions (including LRNC and IPH)
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: Volume of LRNC
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: %LRNC volume
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: Volume of IPH
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: %IPH volume
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: Volume of IPH adjusted for plaque volume
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: Volume of IPH adjusted for plaque volume and volume of LRNC
Number of subjects: 687
Study: 31262378

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31262581

Group type: EXPERIMENTAL
Intervention: 13 mm needle
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 25 mm needle
Number of subjects: 65
Study: 31262585

Group type: EXPERIMENTAL
Intervention: Hecolin® vaccine (3 doses at day 0, month 1, month 6)
Number of subjects: 601

Group type: COMPARATOR
Intervention: Safety control group (no intervention)
Number of subjects: 601
Study: 31262608

Group type: EXPERIMENTAL
Intervention: Serenat Scale (self-report questionnaire, 20 items, scored on a 4-point Likert scale from 0 to 3)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Serenat Scale
Number of subjects: 193
Study: 31262783

Group type: EXPERIMENTAL
Intervention: CD19-specific chimeric antigen receptor (CAR) T cells administered following high-dose chemotherapy and autologous stem cell transplantation (HDT-ASCT) on days +2 and +3.
Number of subjects: 15
Study: 31263030

Group type: EXPERIMENTAL
Intervention: CRS-207
Number of subjects: 35
Study: 31263406

Group type: EXPERIMENTAL
Intervention: Active ASN electrical stimulation (10 Hz)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham ASN electrical stimulation
Number of subjects: 15
Study: 31263598

Group type: EXPERIMENTAL
Intervention: Sentry bioconvertible IVC filter
Number of subjects: 129
Study: 31263700

Group type: EXPERIMENTAL
Intervention: Vegetarian dietary patterns
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 31263727

Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA) injection
Number of subjects: 86

Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 86
Study: 31263960

Group type: EXPERIMENTAL
Intervention: Daily physical activity assessed in steps/day using an arm-worn accelerometer (SenseWear) over 1 week.
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 6-minute walking distance (6MWD) as an independent predictor of daily steps.
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Correlation of daily physical activity with hemodynamics and other outcomes.
Number of subjects: 39
Study: 31264073

Group type: EXPERIMENTAL
Intervention: Trisodium citrate 4%
Number of subjects: 396

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 396
Study: 31264178

Group type: EXPERIMENTAL
Intervention: Edmonton Obesity Staging System (EOSS)
Number of subjects: 9437

Group type: EXPERIMENTAL
Intervention: Sleeve Gastrectomy (SG)
Number of subjects: 9437

Group type: EXPERIMENTAL
Intervention: One-Anastomosis Gastric Bypass (OAGB)
Number of subjects: 9437

Group type: EXPERIMENTAL
Intervention: Roux-en Y Gastric Bypass (RYGB)
Number of subjects: 9437
Study: 31264386

Group type: EXPERIMENTAL
Intervention: Lung diffusing capacity for nitric oxide (DLNO) measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lung diffusing capacity for carbon monoxide (DLCO) measurement
Number of subjects: 0
Study: 31264693

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) over right posterior superior temporal sulcus (rpSTS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) over right occipital face area (rOFA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bilateral fusiform face area (FFA) and right occipital face area (rOFA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bilateral human motion-selective area MT+
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bilateral posterior superior temporal sulcus (pSTS)
Number of subjects: 0
Study: 31264957

Group type: EXPERIMENTAL
Intervention: Seegene RV15 multiplex PCR
Number of subjects: 0
Study: 31265120

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 18
Study: 31265819

Group type: EXPERIMENTAL
Intervention: Through-the-scope (TTS) stent placement
Number of subjects: 32
Study: 31265917

Group type: EXPERIMENTAL
Intervention: Hepatic artery ligation and extrahepatic collaterals division (HALED)
Number of subjects: 19
Study: 31266056

Group type: EXPERIMENTAL
Intervention: Tacrolimus MR4
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ciclosporin and Tacrolimus
Number of subjects: 0
Study: 31266223

Group type: EXPERIMENTAL
Intervention: Implantable EEG-based brain monitoring and seizure prediction system
Number of subjects: 15
Study: 31266741

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) recombinant human IL-15 (rhIL-15) at escalating doses of 0.3-1.0 μg/kg for 12 consecutive days after lymphodepleting chemotherapy and haploidentical NK cells.
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) recombinant human IL-15 (rhIL-15) at 2.0 μg/kg, given once per day for 10 days after lymphodepleting chemotherapy and haploidentical NK cells.
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) rhIL-15
Number of subjects: 42

Group type: COMPARATOR
Intervention: Intravenous (IV) rhIL-15
Number of subjects: 42
Study: 31267239

Group type: EXPERIMENTAL
Intervention: HFdEF (LVEF < 50% at 1 year)
Number of subjects: 471

Group type: COMPARATOR
Intervention: Persistent HFpEF (LVEF ≥ 50% both at admission and 1 year)
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Natriuretic peptide level > median
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Use of beta-blockers, renin-angiotensin system inhibitors, and mineralocorticoid receptor antagonists
Number of subjects: 471
Study: 31267365

Group type: EXPERIMENTAL
Intervention: Knee extensions with elastic band
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: One-legged squat (and sit to stand)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Strength training exercises in more simple forms (e.g. elastic bands, body weight)
Number of subjects: 24
Study: 31267801

Group type: EXPERIMENTAL
Intervention: Adalimumab with ≥12 mg/week methotrexate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31267973

Group type: EXPERIMENTAL
Intervention: Postoperative capecitabine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ado-trastuzumab emtansine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant systemic therapy
Number of subjects: 0